All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-09-15T13:13:31.000Z

Efficacy and safety of CAR T-cell therapies produced in academic centers

Sep 15, 2023
Share:
Learning objective: After reading this article, learners will recall the key efficacy and safety data of decentralized manufactured CAR T-cell products.

Bookmark this article

Chimeric antigen receptor (CAR) T-cell therapy, an advanced therapy medicinal product, is regulated by the European Medicines Agency (EMA) as well as other federal and regional authorities.1 All products must adhere to the good manufacturing practice standards, defined as potent products manufactured safely according to standardized methods under closely controlled, reproducible, and auditable conditions.1

Historically, BioPharma has supplied the majority of CAR T-cell products; however, several academic centers have recently developed point-of-care manufacturing capabilities with the aim of improving patient access and streamlining costs.1

Two CAR T-cell products have been recently developed in academic settings, and pilot studies for each have evaluated the safety and efficacy of these potential therapies. The first product, ARI0002h, was investigated in the pilot CARTBCMA-HCB-01 study (NCT04309981) by Caldes et al.2 The second product, HBI0101, was evaluated in a phase I study (NCT04720313) by Asherie et al.3 Here, we summarize the key results from both trials.

ARI0002h2

Study design

This was a single-arm multicenter, open-label pilot study. The eligibility criteria, dosing schedule, and study endpoints were reported previously by the Multiple Myeloma Hub.

Results

A total of 30 patients with relapsed/refractory multiple myeloma received a CAR T-cell infusion, and their baseline characteristics are shown in Table 1.

Table 1. Baseline patient characteristics*

Characteristic, % (unless otherwise stated)

N = 30

Age, years

61

Sex

              Male

60

              Female

40

Median time since diagnosis, years

4.7

ISS stage

              I

20

              II

32

              III

48

ECOG Performance Status

              0

62

              1

31

              2

7

High-risk cytogenetics

33

              TP53 alterations

23

              t(4;14)

13

              t(14;16)

3

Previous lines of therapy

              Triple exposed

100

              Triple refractory

67

              Penta exposed

37

              Penta refractory

23

              Refractory to the last line

100

ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System.
*Adapted from Caldes, et al.2

  • All patients received Fractions 1 and 2.
  • 86% of patients received the booster dose.
    • In 19 of the 24 patients who were reinfused, 3 × 10⁶ CAR-positive cells per kg were available for the booster dose.
    • Overall, 1.8 × 10⁶ CAR-positive cells per kg were available for 3 patients, and 1.2 × 10⁶ CAR-positive cells per kg were available for 2 patients.
  • The median manufacturing time for ARI0002h was 10 days (interquartile range [IQR], 9–10 days).
  • The mean transduction rate was 56%.
  • All except one of the final CAR T-cell products were successfully obtained on the first attempt.
  • The median time from apheresis reception to product liberation was 30 days (IQR, 26–36 days; range, 19–45 days).
  • For patients requiring urgent treatment, the product was released in as little as 19 days.
  • The overall response rate in the first 100 days post infusion was 100% (Figure 1).

Figure 1. Patient response rates in the first 100 days after ARI0002h infusion* 

CR, complete response; ORR, overall response rate; PR, partial response; VGPR, very good partial response.
*Adapted from Caldes, et al.2

  • The median time to complete response was 3.8 months (IQR, 1.0–11.6 months).
  • Measurable residual disease was evaluable in 73% of patients, of which 95% experienced a negative result.
  • A post hoc analysis, with a median follow-up of 18 months, showed response rates had deepened over time (Table 2)

Table 2. Response rates from the post hoc analysis*

Response, %

N = 30

Overall response

100

Complete response

67

Very good partial response

27

Partial response

7

*Adapted from Caldes, et al.2

  • The median progression-free survival was 14.5 months (95% confidence interval [CI], 12.8–not reached).
  • Median overall survival and duration of response were not reached (95% CI, 8.0–not reached and 95% CI, 12.9–not reached, respectively).
  • During an interim analysis at a median follow-up of 12.1 months, 33% of patients had discontinued treatment.
    • Of these, 80% experienced disease progression and the remainder died without progression.
    • There were no treatment discontinuations due to manufacturing failures.
  • Cytokine release syndrome (CRS) was experienced by 80% of patients
    • There were no Grade ≥3 events
    • The median time to onset was 7 days (IQR, 5–8 days).
    • The median duration of symptoms was 2 days (IQR, 0–14 days).
  • There were no cases of immune effector cell-associated neurotoxicity syndrome or other late neurotoxic effects.
  • There was one mild infusion reaction and one case of moderate tumor lysis syndrome.
  • The most common Grade ≥3 adverse events experienced by patients are shown in Table 3.

Table 3. All Grade ≥3 adverse events*

Adverse event (%)

N = 30

Anemia

10

Neutropenia

70

Thrombocytopenia

47

Pyrexia

7

Lymphocytosis

3

Lymphopenia

3

Febrile neutropenia

3

Diarrhea

3

Alanine aminotransferase increased

3

Aspartate aminotransferase increased

3

Leishmaniasis

3

Rhinovirus infection

3

Septic shock

3

Severe acute respiratory syndrome

3

Staphylococcal bacteremia

3

COVID-19

3

Head injury

3

Seizure

3

Acute kidney injury

3

*Adapted from Caldes, et al.2

HBI01013

Study design

This was a single-center, phase I study. The eligibility criteria, dosing schedule, and study endpoints are shown in Figure 2.

Figure 2. Eligibility criteria, dosing schedule, and study endpoints* 

ECOG, Eastern Cooperative Oncology Group; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RRMM, relapsed/refractory multiple myeloma.
*Adapted from Asherie, et al.3

Results

A total of 20 patients with relapsed/refractory multiple myeloma received a CAR T-cell infusion. Baseline characteristics are shown in Table 4.

Table 4. Baseline patient characteristics*

Characteristic, % (unless otherwise stated)

N = 20

Median age, years

62

Sex

              Male

40

              Female

60

Median time since diagnosis, months

55

R-ISS

              I

5

              II

55

              III

10

ECOG Performance Status

              0

35

              1

20

              2

45

Cytogenetic abnormalities

              High risk

50

              Standard risk

60

              Unknown

5

Median previous lines of therapy, n

6

ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System.
*Adapted from Asherie et al.3

  • Drug products were successfully generated from fresh (n = 19) and cryopreserved (n = 1) raw materials
  • There were no production failures, and product manufacturing was successful for all patients
    • Three patients received bridging therapy during the manufacturing period
  • A total of 18 patients underwent lymphodepletion
  • All patients were infused with fresh drug product after 10 days of production
  • The median duration of hospitalization post infusion was 17 days
    • Most patients were discharged after a maximum of 25 days
  • The median follow up was 136 days
  • The overall response rate was 75% (Figure 3)
    • 50% in Cohort 1, and 85% in Cohorts 2 and 3

Figure 3. Response rates for patients treated with HBI0101* 

CR, complete response; sCR, stringent complete response; MRD, measurable residual disease; ORR, overall response rate; VGPR, very good partial response.
*Adapted from Asherie, et al.3

  • The best response was achieved 1 month post infusion
  • The median progression-free survival was 160 days
  • The median overall survival was 308 days
  • All Grade 3 and 4 adverse events experienced by the total patient population are shown in Table 5

Table 5. All Grade 3 and 4 adverse events*

Adverse event, %

N = 20

Hematologic ≤28 days

              Neutropenia

100

              Thrombocytopenia

60

              Anemia

65

              Lymphopenia

100

              Febrile neutropenia

75

Hematologic >28 days

              Neutropenia

30

              Thrombocytopenia

35

              Lymphopenia

30

              Hypogammaglobulinemia

25

Other ≤28 days

              Elevated liver enzymes

10

              Sepsis

15

              Infectious gastroenteritis

5

              Pulmonary edema

5

Other >28 days

              Atrial fibrillation

5

              Pulmonary edema

5

              Elevated liver enzymes

5

              Pulmonary embolism

5

*Adapted from Asherie et al.3

CRS of any grade was experienced by 90% of patients. The median duration was 2 days, and there were no Grade ≥3 events; however, a higher rate of Grade 2 CRS was noted in Cohorts 3 and 2 compared with Cohort 1 (Figure 4).

Figure 4. Rate of CRS in Cohorts 1, 2, and 3* 

*Adapted from Asherie, et al.3

  • There were no immune effector cell-associated neurotoxicity syndrome events.
  • There were no treatment-related mortalities, though eight patients died due to disease progression and one died due to COVID-19.

Conclusion

Overall, both products demonstrated deep and sustained responses in patients with heavily relapsed or refractory multiple myeloma. Both the response rates and safety results were in line with those of currently approved therapies, as well as results reported in the literature. However, the relatively short median follow-up time of 136 days from the first study was cited as a limitation, as well as a small sample size; this led to wide 95% CIs in the second study. While access to CAR T-cell therapy remains limited due to logistical and financial constraints, these two academically developed products highlight the potential in broadening access for patients by offering reduced vein-to-vein time, greater manageability, and reduced financial burden, while simultaneously testifying to the capability of academic institutions in producing this advanced medicinal technology. The requirement of local current good manufacturing practice facilities and trained staff remains an overall barrier; however, the introduction of semi-automated manufacturing platforms has the potential to standardize the process across multiple sites.

  1. Delgado J, Roddie C, Schmitt M, et al. Point-of-care Production of CAR-T Cells. In: The EBMT/EHA CAR-T Cell Handbook. Springer, Cham; 2022. DOI: 1007/978-3-030-94353-0_8
  2. Oliver-Caldés A, González-Calle V, Cabañas V, et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023;24(8):913-924. DOI: 1016/S1470-2045(23)00222-X
  3. Asherie N, Kfir-Erenfeld S, Avni B, et al. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: Results from a phase I clinical trial. Haematologica. 2022;108(7):1827-1839. DOI: 3324/haematol.2022.281628

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox